카테터 유도 혈전용해 기기 시장 보고서 : 전달 모드, 적응증, 최종사용자, 지역별(2025-2033년)

The global catheter-directed thrombolysis devices market size reached USD 394.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 591.6 Million by 2033, exhibiting a growth rate (CAGR) of 4.61% during 2025-2033. The growing prevalence of chronic diseases, the rising consumer awareness about the importance of early detection and treatment of pulmonary embolism, and significant improvements in the healthcare infrastructure are some of the major factors propelling the market.

Catheter-directed thrombolysis devices are advanced medical tools used to treat blood clots that form within the body's blood vessels. These devices are specifically designed to deliver thrombolytic agents directly to the site of the clot, where they work to dissolve the obstruction and restore blood flow. The procedure involves the insertion of a catheter, a thin, flexible tube, into the affected blood vessel under image guidance, such as an X-ray or ultrasound. Through the catheter, a clot-dissolving medication is delivered directly to the clot or infused into the blood vessel surrounding it. Catheter-directed thrombolysis has proven to be highly effective in quickly restoring blood flow, reducing the risk of long-term complications, and preserving the functionality of the affected organ or limb. It is commonly used to treat conditions, such as deep vein thrombosis (DVT), pulmonary embolism, peripheral arterial occlusions, and other vascular disorders.

Catheter-Directed Thrombolysis Devices Industry Segmentation:

Breakup by Delivery Mode:

• Directly Delivery to Blood Clot
• Positioning Medical Device at Clot Site

Directly delivering thrombolytic agents to the blood clot is a significant delivery mode in catheter-directed thrombolysis. In this approach, the catheter is inserted directly into the blood vessel where the clot is located, ensuring precise and targeted administration of the thrombolytic medication. This method allows for a concentrated and localized action, effectively dissolving the clot and restoring blood flow without affecting other parts of the circulatory system.

On the other hand, the positioning of a medical device at the clot site is a delivery mode in catheter-directed thrombolysis. These devices may include mechanical thrombectomy devices, such as rotating catheters or aspiration systems. This delivery mode is particularly beneficial in cases where direct infusion of thrombolytic agents may not be suitable, such as in large or resistant clots, or when the risk of bleeding from medication is a concern.

Breakup by Indication:

• Pulmonary Embolism (PE)
• Deep Vein Thrombosis (DVT)
• Stroke
• Others

Pulmonary embolism is a critical medical condition and a leading indication segment in the catheter-directed thrombolysis market. PE occurs when a blood clot, often originating from deep veins in the legs, travels through the bloodstream and lodges in the arteries of the lungs, causing a potentially life-threatening obstruction. Catheter-directed thrombolysis is a highly effective treatment for PE as it rapidly dissolves the clot and restores blood flow to the lungs.

On the other hand, deep vein thrombosis is another major indication segment in the catheter-directed thrombolysis market. DVT occurs when a blood clot forms in a deep vein, most commonly in the legs. Catheter-directed thrombolysis for DVT not only alleviates symptoms and reduces the risk of severe complications but also plays a crucial role in preventing long-term issues, such as chronic venous insufficiency. As DVT is a prevalent and potentially serious condition, the demand for catheter-directed thrombolysis devices remains high in the market.

Breakup by End User:

• Hospitals
• Others

Hospitals represent the leading market segment

Hospitals serve as central hubs for medical care and are equipped with advanced facilities, skilled healthcare professionals, and specialized departments, making them ideal settings for performing catheter-directed thrombolysis procedures. The complexity and critical nature of vascular diseases and thrombotic disorders often require a multidisciplinary approach involving interventional radiologists, vascular surgeons, cardiologists, and other medical specialists available in a hospital environment. These medical professionals collaborate to diagnose and treat patients with conditions, including pulmonary embolism, deep vein thrombosis, peripheral arterial occlusions, and other vascular obstructions. Moreover, hospitals have access to state-of-the-art imaging technologies, such as fluoroscopy, ultrasound, and computed tomography (CT), which aid in precise catheter navigation and real-time visualization of the clot during the procedure. Additionally, hospitals maintain a comprehensive range of medical equipment and devices, including the latest catheter-directed thrombolysis technologies, to ensure optimal patient care.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (United States and Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Russia and the rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, Indonesia and rest of Asia-Pacific), Latin America (Brazil, Mexico and rest of Latin America) and the Middle East and Africa. According to the report, North America represents the leading market.

The market in North America is primarily being driven due to advanced healthcare infrastructure, a well-established medical device industry, and a high prevalence of vascular diseases in the region. The region's strong emphasis on healthcare research and innovation has led to the development of cutting-edge catheter-directed thrombolysis devices, further driving their adoption.

The market in Asia Pacific is witnessing an increase in the aging population, which is more susceptible to vascular conditions, further augmenting the demand for these devices. The presence of leading medical device manufacturers and ongoing research and development efforts also contribute to the growth of the market in the Asia Pacific. With a combination of a vast patient pool, improving healthcare facilities, and a focus on technological advancements, the Asia Pacific region is expected to maintain its dominant position in the catheter-directed thrombolysis devices market.

Competitive Landscape:

Companies in the market are heavily investing in research and development to improve the design, efficacy, and safety of their catheter-directed thrombolysis devices. They are focused on creating innovative technologies and drug delivery mechanisms to enhance the clot-dissolving process and minimize the risk of bleeding complications. Moreover, leading players are conducting clinical trials to gather evidence of safety and efficacy and obtaining regulatory approvals from health authorities to market their devices globally. These processes helped establish the credibility and compliance of their products. Additionally, several companies are providing training and educational programs to healthcare professionals to ensure they had the necessary skills and knowledge to use catheter-directed thrombolysis devices effectively and safely. To stay competitive, major companies are launching new catheter-directed thrombolysis devices or upgraded existing ones. These products were often designed to be more user-friendly, precise, and capable of achieving better patient outcomes.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• AngioDynamics, Inc.
• Boston Scientific Corporation
• Inari Medical, Inc.
• iVascular, S.L.U
• Medtronic Plc
• Penumbra, Inc.
• Straub Medical AG (Becton, Dickinson, and Company)
• Teleflex Incorporated
• Thrombolex Inc.

Key Questions Answered in This Report

• 1.How big is the catheter-directed thrombolysis devices market?
• 2.What is the future outlook of catheter-directed thrombolysis devices market?
• 3.What are the key factors driving the catheter-directed thrombolysis devices market?
• 4.Which region accounts for the largest catheter-directed thrombolysis devices market share?
• 5.Which are the leading companies in the global catheter-directed thrombolysis devices market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Catheter-Directed Thrombolysis Devices Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Delivery Mode

• 6.1 Directly Delivery to Blood Clot
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Positioning Medical Device at Clot Site
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Indication

• 7.1 Pulmonary Embolism (PE)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Deep Vein Thrombosis (DVT)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Stroke
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Others
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Europe
  • 9.2.1 Germany
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 France
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 United Kingdom
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 Italy
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Spain
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Russia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Rest of Europe
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Asia-Pacific
  • 9.3.1 China
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 India
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 Japan
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Australia
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 South Korea
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Indonesia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Rest of Asia-Pacific
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Rest of Latin America
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AngioDynamics, Inc
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT
  • 14.3.2 Boston Scientific Corporation
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT
  • 14.3.3 Inari Medical, Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
  • 14.3.4 iVascular, S.L.U
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Medtronic Plc
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT
  • 14.3.6 Penumbra, Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 Straub Medical AG (Becton, Dickinson and Company)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT
  • 14.3.8 Teleflex Incorporated
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT
  • 14.3.9 Thrombolex Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio